News continues to be generally positive for the sector and there is no reason to suspect that the broader trend for the sector will be higher. Obviously, there will be retrenchments and pullbacks but those will be opportunities to add to positions just as the rallies in the bear market were opportunities to trim positions. […]
October 14th Biotech Update
Over the past few days, biotech and pharmaceutical stocks have seen mixed but generally positive moves sparked by deal news and strong individual performers. This environment reinforces the more positive sentiment around the sector but with a preference now being placed on pipelines with strong differentiation, regulatory path clarity, or acquisition potential. It seems the […]
October 10th Biotech Update
There is a lot still to summarize and talk about and I will be slowly chipping away at what I see are key developments for the broader market as well as those companies I have followed in the past. This has a little bit of both to end the week. BTIG hosted a webcast with […]
October 8th Biotech Update
Biotech sentiment is cautiously constructive: the XBI is up about 15% year-to-date which is outpacing the broader health sector. While we have seen deals, the next stage would be the IPO window creaking open again—2025 has logged ~165 U.S. IPOs across sectors and fresh biopharma filings like BillionToOne point to improving risk appetite, even if […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
